Transitions in SPMS Diagnosis and DMT Use Following Siponimod Reimbursement: Evidence from the Czech ReMuS Registry (2016-2023)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F25%3A10003520" target="_blank" >RIV/27661989:_____/25:10003520 - isvavai.cz</a>

Výsledek na webu

<a href="https://journals.sagepub.com/doi/epub/10.1177/13524585251370533" target="_blank" >https://journals.sagepub.com/doi/epub/10.1177/13524585251370533</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/13524585251370533" target="_blank" >10.1177/13524585251370533</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Transitions in SPMS Diagnosis and DMT Use Following Siponimod Reimbursement: Evidence from the Czech ReMuS Registry (2016-2023)

Popis výsledku v původním jazyce

This study examines national trends in the diagnosis of secondary progressive multiple sclerosis (SPMS) in the Czech Republic between 2016 and 2023 using data from the ReMuS registry. Patients were classified either by clinical diagnosis (Cohort C; n = 722) or via the algorithm by Lorscheider et al. (Cohort D; n = 1,441). Trends were compared before and after siponimod reimbursement in 2021, assessing age, EDSS, relapse history, and exposure to disease‑modifying therapies (DMTs). Clinical SPMS diagnoses increased after 2021, whereas algorithm‑based identification remained stable. Patients were older at diagnosis and had greater prior DMT exposure, particularly high‑efficacy therapies; meanwhile, the proportion of untreated patients decreased substantially. Persistent discrepancies between clinical and algorithmic classifications highlight ongoing variability in diagnostic practice and the need for more standardised criteria for SPMS identification.

Název v anglickém jazyce

Transitions in SPMS Diagnosis and DMT Use Following Siponimod Reimbursement: Evidence from the Czech ReMuS Registry (2016-2023)

Popis výsledku anglicky

This study examines national trends in the diagnosis of secondary progressive multiple sclerosis (SPMS) in the Czech Republic between 2016 and 2023 using data from the ReMuS registry. Patients were classified either by clinical diagnosis (Cohort C; n = 722) or via the algorithm by Lorscheider et al. (Cohort D; n = 1,441). Trends were compared before and after siponimod reimbursement in 2021, assessing age, EDSS, relapse history, and exposure to disease‑modifying therapies (DMTs). Clinical SPMS diagnoses increased after 2021, whereas algorithm‑based identification remained stable. Patients were older at diagnosis and had greater prior DMT exposure, particularly high‑efficacy therapies; meanwhile, the proportion of untreated patients decreased substantially. Persistent discrepancies between clinical and algorithmic classifications highlight ongoing variability in diagnostic practice and the need for more standardised criteria for SPMS identification.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis Journal

ISSN

1352-4585

e-ISSN

1477-0970

Svazek periodika

31

Číslo periodika v rámci svazku

3 Supplement

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

1430-1431

Kód UT WoS článku

001603659904326

EID výsledku v databázi Scopus

—